Beijing Wantai Biological Pharmacy Enterprise Co Ltd. Stock Analysis 603392.SS

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and equipment, and vaccines. The company is headquartered in Beijing, Beijing and currently employs 4,116 full-time employees. The company went IPO on 2020-04-29. The firm operates two segments. Diagnostic segment produces and sells in vitro diagnostic reagents and instruments suitable for in vitro diagnostic reagent testing. Vaccine segment produces and sells vaccines. The in vitro diagnostic reagents mainly include enzyme-linked immunosorbent assay reagents, colloidal gold diagnostic reagents, biochemical diagnostic reagents, chemiluminescent diagnostic reagents, and others. The in vitro diagnostic instruments include fully automatic chemiluminescent immunoassay analyzers, dry fluorescent immunoassay analyzers, fully automatic nucleic acid purification, and others. The vaccines mainly include hepatitis E vaccine, bivalent human papillomavirus (HPV) vaccine and nasal spray COVID-19 vaccine.